Tufts researchers identify potential topical treatment for macular degeneration

New study reports successful use in mice; implications for both forms of AMD

2013-10-10

(Press-News.org) BOSTON (Wednesday, October 9, 2013, 5:00 pm ET) — Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration (AMD) in a study of mice that shows promise for clinical use. The research findings, published today in PLOS ONE, are the first to report successful topical use of a compound capable of inhibiting symptoms associated with both dry AMD (the earlier form) and wet AMD (the rarer, later form) and could represent a breakthrough for treatment of these conditions. AMD is among the leading causes of blindness among the elderly. Currently, there is no treatment for dry AMD, and wet AMD can only be treated with regular injections into the eye.

The team of researchers from Tufts, led by Rajendra Kumar-Singh, Ph.D., reported in their "proof of concept" study that topical application of pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid, a compound called PPADS, inhibits damage to the tissues in the eye that impacts the individual's ability to see color and fine detail, as well as reduces the growth of extraneous blood vessels in the back of the eye related to advanced AMD.

According to the National Eye Institute, more than 7 million people in the United States are at substantial risk of developing AMD. Factors that contribute to the development of AMD include age, diet, smoking, and genetic predisposition. Dry AMD is the more common and less serious stage of AMD, characterized by the slow loss or blurring of central vision in spots. Wet AMD, which almost always begins as dry AMD and only occurs in approximately 10% of AMD patients, is more advanced and characterized by the development of blood vessels in the back of the eye that often leak and damage the surrounding tissues. Only the wet form of AMD can be treated, with an ophthalmologist administering injections every four to 12 weeks that can be uncomfortable, risky, and burdensome to patients. The development of a topical eye-drop treatment that works in both dry and wet AMD could increase treatment adherence and reduce patient discomfort by reducing or removing the need for direct injections.

"An ideal therapy would be one that can be self-administered daily by patients. Further studies are needed to determine safety, dosage, and other factors before advancement of this therapy towards clinical trials, but our study suggests that there's significant promise for the development of self-administered topical treatments for age-related macular degeneration in humans," said senior author Rajendra Kumar-Singh, Ph. D., associate professor of ophthalmology at Tufts University School of Medicine and member of the cell, molecular and developmental biology, genetics, and neuroscience graduate programs the Sackler School of Graduate Biomedical Sciences at Tufts.

To test the effectiveness of a topical application of PPADS, the team of researchers induced the tissue damage and blood vessel growth characteristics of AMD in anesthetized mice. The topical treatment was then administered every 24 hours for three consecutive days. The researchers then examined the eye tissues one week later to assess for progression of the damage and blood vessel growth.

"Our study found that topical application of the PPADS compound works on two fronts. First, it stops the damage to eyes caused by pores formed in the membrane that leads to cell death within the eye by stopping an immune system process known as complement that is responsible for dry AMD. Second, it prevents the formation of the blood vessels that can leak and damage the eye, a process associated with wet AMD" explained first author Kerstin Birke Ph.D., a postdoctoral scholar in the Kumar-Singh lab at Tufts.

### Additional authors of the paper are Erion Lipo, B.A., research assistant in the Kumar-Singh laboratory, and Marco T. Birke, Ph.D., postdoctoral scholar in the Kumar-Singh laboratory.

Research reported in this publication was supported by The Ellison Foundation and the National Eye Institute of the National Institutes of Health under award numbers 1R01EY021805 and 5R01EY013837.

Birke K, Lipo E, Birke MT, Kumar-Singh R (2013) Topical Application of PPADS Inhibits Complement Activation and Choroidal Neovascularization in a Model of Age-Related Macular Degeneration. PLoS ONE 8(10): e76766. doi:10.1371/journal.pone.0076766. Available online at: http://dx.plos.org/10.1371/journal.pone.0076766.

About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, biomedical sciences, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its effect on the advancement of medical science.

If you are a member of the media interested in learning more about this topic, or speaking with a faculty member at Tufts University School of Medicine or another Tufts health sciences researcher, please contact Siobhan Gallagher at 617-636-6586 or Andrea Grossman at 617-636-3728.

ELSE PRESS RELEASES FROM THIS DATE:

Forests most likely to continue shrinking: U of G study

2013-10-10

Forest cover around the world will continue a slow shrinking before stabilizing at a lower level, according to a new study from the University of Guelph. Researchers analyzed forest trends from around the world and developed a mathematical model to show future land use changes. They found the most likely model shows forests will decline from 30 per cent of Earth's land mass today to 22 per cent within the next two centuries. The model discusses different scenarios, such as global forest growth reversing deforestation, or reforestation cut short by renewed losses. ...

Medical experts recommend steps to reduce risk of inadvertent harm to potentially normal pregnancies

2013-10-10

A panel of 15 medical experts from the fields of radiology, obstetrics-gynecology and emergency medicine, convened by the Society of Radiologists in Ultrasound (SRU), has recommended new criteria for use of ultrasonography in determining when a first trimester pregnancy is nonviable (has no chance of progressing and resulting in a live-born baby). These new diagnostic thresholds, published Oct. 10 in the New England Journal of Medicine, would help to avoid the possibility of physicians causing inadvertent harm to a potentially normal pregnancy. "When a doctor tells a ...

Whites more prone to certain heart condition than other ethnic groups

2013-10-10

An individual’s race or ethnic background could be a determining factor when it comes to risk of atrial fibrillation, the most frequently diagnosed type of irregular heart rhythm, according to researchers at UC San Francisco. In a study to be published online October 8 and in the November 12 issue of Circulation, researchers discovered that self-described non-Hispanic whites are more likely to develop atrial fibrillation than people from other race or ethnic groups. “We found that consistently, every other race had a statistically significant lower risk of atrial ...

Single gene mutation linked to diverse neurological disorders

2013-10-10

A research team, headed by Theodore Friedmann, MD, professor of pediatrics at the University of California, San Diego School of Medicine, says a gene mutation that causes a rare but devastating neurological disorder known as Lesch-Nyhan syndrome appears to offer clues to the developmental and neuronal defects found in other, diverse neurological disorders like Alzheimer's, Parkinson's and Huntington's diseases. The findings, published in the October 9, 2013 issue of the journal PLOS ONE, provide the first experimental picture of how gene expression errors impair the ...

Big data reaps big rewards in drug safety

2013-10-10

Using the Food and Drug Administration's Adverse Event Reporting System (FAERS), a hospital electronic health records database, and an animal model, a team of researchers at the Icahn School of Medicine at Mount Sinai report that by adding a second drug to the diabetes drug rosiglitazone, adverse events dropped enormously. That suggests that drugs could be repurposed to improve drug safety, including lowering the risk of heart attacks. The research is published online Oct. 9 in the journal Science Translational Medicine. The approach is part of an emerging strategy ...

Skill ratings predict which surgeons perform safer surgeries

2013-10-10

ANN ARBOR, Mich. – Video ratings data of surgeons' operating skills successfully predicted whether patients would suffer complications after they leave the operating room, according to a University of Michigan Health System study. The study assessed the relationship between the technical skill of 20 bariatric surgeons and post-surgery complications in 10,343 patients undergoing common, but complex laparoscopic gastric bypass surgery. High skill surgeons, as rated by their peers, had significantly fewer post-surgery complications such as bleeding or infections, according ...

New technique allows anti-breast cancer drugs to cross blood-brain barrier

2013-10-10

Some breast cancer drugs can penetrate the blood-brain barrier (BBB), but they have not been very effective against brain metastases, whereas other, more effective anti-breast cancer drugs cannot penetrate the BBB at all. In a study published October 9 in the Journal of the National Cancer Institute, researchers used a new approach to selectively permeabilize the BBB at sites of brain metastases, even those 200 times smaller than currently detectable in the clinic. To facilitate drug delivery to brain metastases, John Connell of the CRUK/MRC Gray Institute for Radiation ...

New strategy to treat multiple sclerosis shows promise in mice

2013-10-10

LA JOLLA, CA—October 9, 2013—Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers. One of the newly identified compounds, a Parkinson's disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies. "We're excited about ...

Study in Nature reveals urgent new time frame for climate change

2013-10-10

Ecological and societal disruptions by modern climate change are critically determined by the time frame over which climates shift. Camilo Mora and colleagues in the College of Social Sciences' Department of Geography at the University of Hawaii, Manoa have developed one such time frame. The study, entitled "The projected timing of climate departure from recent variability," will be published in the October 10 issue of Nature and provides an index of the year when the mean climate of any given location on Earth will shift continuously outside the most extreme records experienced ...

Evidence for a new nuclear 'magic number'

2013-10-10

Researchers have come one step closer to understanding unstable atomic nuclei. A team of researchers from RIKEN, the University of Tokyo and other institutions in Japan and Italy has provided evidence for a new nuclear magic number in the unstable, radioactive calcium isotope 54Ca. In a study published today in the journal Nature, they show that 54Ca is the first known nucleus with 34 neutrons (N) where N = 34 is a magic number. The protons and neutrons inside the atomic nucleus exhibit shell structures in a manner similar to electrons in an atom. For naturally stable ...

Inhibition of cyclooxygenase-2 upregulates the nuclear factor erythroid 2-related factor 2 signaling pathway to mitigate hepatocyte ferroptosis in chronic liver injury

Tufts researchers identify potential topical treatment for macular degeneration

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: